Prostaglandins and leukotrienes

Encyclopedia of Human Nutrition

Volumn , Issue , 2005, Pages 42-49

  Caughey, G E ^a   James, M J ^a   Cleland, L G ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052652910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-12-226694-3/00268-4     Document Type: Chapter

References (17)

1. Bergström S., Danielsson H., Klenberg D., Samuelsson B. The enzymatic conversion of essential fatty acids into prostaglandins. Journal of Biological Chemistry 1964, 239:4006-4009.
2. Boers M. NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001, 357:1222-1223.
3. Dyerberg J., Bang H.O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979, 2:433-435.
4. Drazen J.M., Israel E., O'Bryne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. The New England Journal of Medicine 1999, 340:197-206.
5. Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. The New England Journal of Medicine 2001, 345:433-442.
6. Funk C.D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001, 294:1871-1875.
7. Harris R.C., Breyer M.D. Physiological regulation of COX-2 in the kidney. American Journal of Physiology 2001, 281:F1-F11.
8. James M.J., Gibson R.A., Cleland L.G. Dietary polyunsaturated fatty acids and inflammatory mediator production. American Journal of Clinical Nutrition 2000, 71:343s-348s.
9. Hui Y., Funk C.D. Cysteinyl leukotriene receptors. Biochemical Pharmacology 2002, 64:1549-1557.
10. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., Fitzgerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Science USA 1999, 96:272-277.
11. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. The Journal of Clinical Investigation 2001, 108:25-30.
12. Prescott S.M. Is cyclooxygenase-2 the alpha and the omega in cancer?. The Journal of Clinical Investigation 2000, 105:1511-1513.
13. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis and biological effects. Science 1987, 237:1171-1176.
14. 4. Journal of Biological Chemistry 1989, 264:19469-19472.
15. 2 in structure-function is a challenge for structure-based therapeutics. Proceedings of the National Academy of Science USA 2003, 100:8609-8611.
16. Smith W.L., Lanenbach R. Why there are two cyclooxygenase isozymes. The Journal of Clinical Investigation 2001, 107:1491-1495.
17. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenase: structural, cellular and molecular biology. Annual Review of Biochemistry 2000, 69:145-182.